19625-92-4

Basic information

• Product Name: (E)-5,5-diphenyl-2,4-pentadienoic acid
• CAS NO: 19625-92-4
• Molecular Weight: 250.297
• Mol File: 19625-92-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (E)-5,5-diphenyl-2,4-pentadienoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-5,5-diphenyl-2,4-pentadienoic acid(19625-92-4)
• EPA Substance Registry System: (E)-5,5-diphenyl-2,4-pentadienoic acid(19625-92-4)

Safety Data

• Hazardous Substances Data: 19625-92-4(Hazardous Substances Data)

Upstream product

• 101723-21-1 (E)-methyl 5,5-diphenylpenta-2,4-dienoate 
• 119-61-9 benzophenone 
• 1117-71-1 methyl 4-bromocrotonate 
• 24892-82-8 1-bromo-2-(1-phenylpropen-1-yl)benzene 
• 120342-72-5 (E)-5,5-diphenyl-2,4-pentadieneoic acid ethyl ester 

Downstream Products

• 1002123-50-3 (E)-N-(isoquinolin-5-yl)-5,5-diphenyl-2,4-pentadinenamide 
• 23434-73-3 5,5-diphenylpentanoic acid 
• 19625-87-7 4-(5,5-diphenyl-penta-2,4-dienoyl)-morpholine 
• 406726-00-9 2E-6-(5,5-Diphenylpenta-2,4-dienoylamino)hexanoic acid methyl ester 

Relevant articles and documents

Highly Stereoselective Synthesis of 1,3-Dienes through an Aryl to Vinyl 1,4-Palladium Migration/Heck Sequence

An efficient aryl to vinyl 1,4-palladium migration/Heck sequence was developed for the stereoselective synthesis of 1,3-dienes. High stereoselectivity was observed not only for 1,3-dienes bearing two similar aryl groups at terminal positions, but also for

PENTADIENAMIDE DERIVATIVE

The present invention provides a pentadienamide derivative represented by the formula (I): (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R2 represents substitu

Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor

A series of N-[4-(3-pyridinyl)butyl]-5,5-disubstituted-pentadienamides was prepared and evaluated for PAF-antagonist activity. Compounds were assayed in vitro in a PAF-binding assay employing washed, whole dog platelets as the receptor source and in vivo after intravenous or oral administration for their ability to prevent PAF-induced bronchoconstriction in guinea pigs. Criteria required for good oral activity in the latter model include an (E,E)-5-phenyl-2,4-pentadienamide, a second phenyl or a four- or five-carbon alkyl moiety in the 5-position of the diene, and an (R)-[1-alkyl-4-(3-pyridinyl)butyl] substituent on the carboxamide nitrogen atom. The alkyl substituent on this side chain can be methyl, ethyl, or cyclopropyl. Two members of this series, [R-(E)]-5,5-bis(4-methoxyphenyl)-N-[1-methyl-4-(3-pyridinyl)butyl]-2,4- pentadienamide (31) and [R-(E,E)]-5-(4-methoxyphenyl)-N-[1-methyl-4-(3-pyridinyl)butyl]-2,4- decadienamide (58), were selected for further pharmacological evaluation. Both were found to be substantially longer acting after oral administration than the corresponding S enantiomers in the guinea pig bronchoconstriction assay. A second in vivo model used to evaluate PAF antagonists determines the ability of test compounds to decrease the area of skin wheals induced by an intradermal injection of PAF. In this model, using both rats and guinea pigs, compounds 31 and 58 were found to be as active as the reference PAF antagonist 3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3- a][1,4]diazepin-2-yl]-1-(4-morpholinyl)-1-propanone (45).